ALK and non-small cell lung carcinoma: Brigatinib demonstrated superior efficacy in the ALTA-1L study as a first-line treatment for ALK-positive NSCLC, achieving an mPFS of 24.0 months compared to 11.0 months with crizotinib (hazard ratio [HR]: 0.49, 95% CI: 0.35–0.68), along with a favorable safety profile and enhanced intracranial activity [22].